Scilex annoucnes acceptance of abstract for poster, oral presentation at AAPM

Scilex Holding announced acceptance of an abstract for poster and oral presentation at the 2024 Annual Meeting of the American Academy of Pain Medicine, AAPM, which will take place on March 7-10, 2024 in Scottsdale, Arizona. Titled: Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis: In this retrospective analysis of OPTUM claims data, researchers evaluated over 6,000 patients with neuropathic pain who were treated with either ZTlido or a generic lidocaine 5% patch and were also receiving an opioid. The study demonstrated a greater proportion of patients treated with ZTlido were able to either decrease or discontinue opioids compared to patients treated with a generic lidocaine 5% patch. In addition, patients treated with ZTlido had a more significant reduction in opioid dose relative to a generic lidocaine 5% patch. Regardless of the type of neuropathic pain, ZTlido was associated with a greater opioid-sparing effect than a generic lidocaine 5% patch. Title: Retrospective Claims Analysis of Decreased Healthcare Visits and Costs with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: In a retrospective analysis of over 889,000 patients, we used Symphony Health claims data to evaluate the impact of ZTlido versus lidocaine 5% patch on healthcare resource utilization, including emergency room visits, office/clinic visits, outpatient visits, and pain procedures. Across the studied care settings, treatment with ZTlido was associated with either a reduction or insignificant increase in healthcare resource utilization, while lidocaine 5% patch was associated with consistently and significantly large increases in healthcare resource utilization. These results are consistent with and confirm early reported data from another retrospective claims analysis.